Apollomics, Inc discovered novel APL-106 (uproleselan) for the treatment of relapsed/refractory Acute Myeloid Leukemia (AML) in China.
AML is an aggressive disease and relapsed/refractory having an extremely poor prognosis in patients.
AML is a blood and bone marrow cancer. It is an aggressive disease which causes the bone marrow to produce immature cells which cannot carry out their normal function and thus results in developing into leukemic white blood cells called myeloblasts. In addition, every year 20,000 new cases of AML generate.
(APL-106) is a late clinical stage first-in-class, targeted inhibitor of E-selectin. In September 2020, the NMPA CDE has granted Investigational New Drug (IND) approval for APL-106 enabling the initiation of a Phase 1 pharmacokinetics (PK) and tolerability study and includes acceptance of a Phase 3 bridging study of APL-106 in combination with chemotherapy in relapsed/refractory AML
APL-106 (uproleselan) has been granted Breakthrough Therapy Designation for the treatment of Acute Myeloid Leukemia in China.
